Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

KETOCONAZOLE

All products: not a benefit

Other products in the same Health Canada class (D01A, D01AC) — coverage varies; not interchangeable

  • Clotrimazole (Clotrimaderm): general benefit, Not a benefit
  • Miconazole nitrate (Micatin): general benefit
  • Betamethasone dipropionate + clotrimazole (Lotriderm Cream): not a benefit
  • Nystatin (Mycostatin): general benefit, Not a benefit
  • Terbinafine (Lamisil): general benefit
  • Ciclopirox (Penlac): not a benefit

Nizoral · DIN 00703974 · 2% · Cr

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2007-08-02 — choose a marketed DIN from the same-category list.Discontinued 2007-08-02 · checked 2026-09-20
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2007-08-02 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2007-08-02 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Nizoral · DIN 00703974 Manufacturer: Janssen Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2007-08-02 · brand NIZORAL CREAM 2% · ATC D01AC08 KETOCONAZOLE · form Cream · route Topical · ingredients KETOCONAZOLE 2 % · company Mcneil consumer healthcare division of johnson & johnson inc · schedule Prescription
Check this DIN again · Health Canada product record

Nizoral: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8378 · Verify on the e-Formulary ↗ (DIN 00703974)

Source record
DIN 00703974: Nizoral Raw flags: notABenefit=Y, sec3=Y Item: 840408034; group id 821; item number 2003; lccId None; manufacturer id JAN Source form: Cr; strength: 2% Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00703974 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8378
Interchangeable products
Ketoderm · DIN 02245662 · $0.4043
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since 2007-08-02 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (84:04:08 Fungicides) and how they are covered

Matched class: 84:04:08 Fungicides

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: MICONAZOLE NITRATE, TERBINAFINE HCL Some products covered without a code (check the product listing): CLOTRIMAZOLE, NYSTATIN, TERCONAZOLE 84:04:08 Fungicides

CLOTRIMAZOLE

· 7 products · General benefit (6), Listed, not a benefit (1) · strengths: 10mg/g, 500mg & 1%, 20mg/g · Cr, Tab & Cr, Vag Cr-App

MICONAZOLE NITRATE

· 1 products · General benefit · strengths: 2% · Cr

CLOTRIMAZOLE & BETAMETHASONE DIPROPIONATE

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1% w/w & 0.05% w/w · Top Cr

NYSTATIN

· 7 products · Listed, not a benefit (3), General benefit (4) · strengths: 100000U/g, 25000U/g · Cr, Oint, Vag Cr

TERBINAFINE HCL

· 1 products · General benefit · strengths: 1% · Cr

CICLOPIROX

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 8% W/W · Top Sol

TERCONAZOLE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 0.4% · Vag Cr

FLUCONAZOLE

· 8 products · Limited Use, codes 235 · strengths: 150mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 84:04:08
Full class listing Related classes: 84:04:04 Antibiotics, 84:04:12 Parasiticides, 84:04:16 Other Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS For the treatment of serious or life-threatening systemic fungal infections in normal, predisposed or immunocompromised patients where alternate therapy is considered inappropriate or has been unsuccessful: systemic candidiasis, chronic mucocutaneous candidiasis, coccidioidomycosis and paracoccidioidomycosis, histoplasmosis and chromomycosis. Its use may also be considered in the treatment of severe, recalcitrant dermatophytoses unresponsive to other forms of therapy. The type of organism responsible for the infection should be identified; however, therapy may be initiated prior to obtaining these results, when clinically warranted. 1 Note: The treatment of fungal infections of the CNS is not recommended; ketoconazole penetrates poorly into the CNS. https://pdf.hres.ca/dpd_pm/00024529.PDF PM date: not printed or not captured Source product: TEVA-KETOCONAZOLE; DIN 02231061; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Nizoral: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026